Role of autophagy in the progression and suppression of leukemias

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 3, 2012, Pages 275-285

  Ekiz, Huseyin Atakan ^a   Can, Geylani ^a   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Autophagy; Cell death; Chemotherapeutic resistance; Leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; BECLIN 1; DAPORINAD; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMATINIB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SELENIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; BECLIN 1 GENE; BLAST CELL CRISIS; BLOOD CELL; CANCER CELL; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG RESISTANCE; GENE; HUMAN; LEUKEMIA; LYSOSOME; LYSOSOME MEMBRANE; MACROAUTOPHAGY; MITOCHONDRION; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PHOTODYNAMIC THERAPY; PROTEIN DEGRADATION; REVIEW;

ANIMALS; AUTOPHAGY; CELL SURVIVAL; ENERGY METABOLISM; HUMANS; LEUKEMIA; LYSOSOMES;

EID: 84856974622     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.03.009     Document Type: Review

References (122)

1. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
2. Todde V., Veenhuis M., van der Klei I.J. Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009, 1792:3-13.
3. Brech A., Ahlquist T., Lothe R.A., Stenmark H. Autophagy in tumour suppression and promotion. Mol Oncol 2009, 3:366-375.
4. Teitell M.A., Mikkola H.K. Transcriptional activators, repressors, and epigenetic modifiers controlling hematopoietic stem cell development. Pediatr Res 2006, 59:33R-39R.
5. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982, 79:7824-7827.
6. Papaemmanuil E., Hosking F.J., Vijayakrishnan J., et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009, 41:1006-1010.
7. Roman-Gomez J., Cordeu L., Agirre X., et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007, 109:3462-3469.
8. Omura-Minamisawa M., Diccianni M.B., Batova A., et al. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res 2000, 6:1219-1228.
9. Roman-Gomez J., Castillejo J.A., Jimenez A., et al. 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002, 99:2291-2296.
10. Mi S., Lu J., Sun M., et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:19971-19976.
11. Sanz G.F., Sanz M.A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
12. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002, 99:1909-1912.
13. Le Beau M.M., Albain K.S., Larson R.A., et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986, 4:325-345.
14. Bizzozero O.J., Johnson K.G., Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. N Engl J Med 1966, 274:1095-1101.
15. Horwitz M., Goode E.L., Jarvik G.P. Anticipation in familial leukemia. Am J Hum Genet 1996, 59:990-998.
16. Horwitz M. The genetics of familial leukemia. Leukemia 1997, 11:1347-1359.
17. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
18. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
19. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
20. Smith M.L., Cavenagh J.D., Lister T.A., Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004, 351:2403-2407.
21. Lee J.W., Kim Y.G., Soung Y.H., et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006, 25:1434-1436.
22. Bollag G., Adler F., elMasry N., et al. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 1996, 271:32491-32494.
23. Barjesteh van Waalwijk van Doorn-Khosrovani S., Spensberger D., de Knegt Y., Tang M., Lowenberg B., Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene 2005, 24:4129-4137.
24. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
25. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
26. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
27. Reed J.C. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998, 25:11-18.
28. Molica S., Mannella A., Crispino G., Dattilo A., Levato D. Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias. Haematologica 1997, 82:555-559.
29. Lagneaux L., Delforge A., Bron D., De Bruyn C., Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91:2387-2396.
30. Castejon R., Vargas J.A., Romero Y., Briz M., Munoz R.M., Durantez A. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Cytometry 1999, 38:224-230.
31. Pekarsky Y., Zanesi N., Aqeilan R.I., Croce C.M. Animal models for chronic lymphocytic leukemia. J Cell Biochem 2007, 100:1109-1118.
32. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
33. Staudt L.M. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003, 348:1777-1785.
34. Tough I.M., Court Brown W.M., Baikie A.G., et al. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism. Lancet 1961, 1:411-417.
35. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
36. Silver R.T. Chronic myeloid leukemia. Hematol Oncol Clin North Am 2003, 17:1159-1173. vi-vii.
37. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
38. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
39. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
40. Baran Y., Salas A., Senkal C.E., et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007, 282:10922-10934.
41. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409.
42. Tsukada M., Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 1993, 333:169-174.
43. Bergamini E. Autophagy: a cell repair mechanism that retards ageing and age-associated diseases and can be intensified pharmacologically. Mol Aspects Med 2006, 27:403-410.
44. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
45. Mizushima N., Ohsumi Y., Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct 2002, 27:421-429.
46. Pattingre S., Espert L., Biard-Piechaczyk M., Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008, 90:313-323.
47. Kihara A., Noda T., Ishihara N., Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001, 152:519-530.
48. Mijaljica D., Prescott M., Klionsky D.J., Devenish R.J. Autophagy and vacuole homeostasis: a case for self-degradation?. Autophagy 2007, 3:417-421.
49. Majeski A.E., Dice J.F. Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol 2004, 36:2435-2444.
50. Dice J.F. Chaperone-mediated autophagy. Autophagy 2007, 3:295-299.
51. Korolchuk V.I., Menzies F.M., Rubinsztein D.C. A novel link between autophagy and the ubiquitin-proteasome system. Autophagy 2009, 5:862-863.
52. Korolchuk V.I., Mansilla A., Menzies F.M., Rubinsztein D.C. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009, 33:517-527.
53. Meijer A.J., Codogno P. Autophagy: regulation and role in disease. Crit Rev Clin Lab Sci 2009, 46:210-240.
54. Corcelle E.A., Puustinen P., Jaattela M. Apoptosis and autophagy: targeting autophagy signalling in cancer cells -'trick or treats'?. FEBS J 2009, 276:6084-6096.
55. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
56. Gunn J.M., Clark M.G., Knowles S.E., Hopgood M.F., Ballard F.J. Reduced rates of proteolysis in transformed cells. Nature 1977, 266:58-60.
57. Kisen G.O., Tessitore L., Costelli P., et al. Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis 1993, 14:2501-2505.
58. Qu X., Yu J., Bhagat G., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
59. Liang X.H., Jackson S., Seaman M., et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676.
60. Takahashi Y., Coppola D., Matsushita N., et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007, 9:1142-1151.
61. Liang X.H., Kleeman L.K., Jiang H.H., et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol 1998, 72:8586-8596.
62. Marino G., Salvador-Montoliu N., Fueyo A., Knecht E., Mizushima N., Lopez-Otin C. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4 C/autophagin-3. J Biol Chem 2007, 282:18573-18583.
63. Levine B. Cell biology: autophagy and cancer. Nature 2007, 446:745-747.
64. Lock R., Debnath J. Extracellular matrix regulation of autophagy. Curr Opin Cell Biol 2008, 20:583-588.
65. Karantza-Wadsworth V., Patel S., Kravchuk O., et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007, 21:1621-1635.
66. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005, 5:726-734.
67. Bursch W., Ellinger A., Kienzl H., et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996, 17:1595-1607.
68. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11:448-457.
69. Opipari A.W., Tan L., Boitano A.E., Sorenson D.R., Aurora A., Liu J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004, 64:696-703.
70. Amaravadi R.K., Yu D., Lum J.J., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007, 117:326-336.
71. Apel A., Herr I., Schwarz H., Rodemann H.P., Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485-1494.
72. Tiwari M., Bajpai V.K., Sahasrabuddhe A.A., et al. Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells. Carcinogenesis 2008, 29:600-609.
73. Ito H., Daido S., Kanzawa T., Kondo S., Kondo Y. Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 2005, 26:1401-1410.
74. Ertmer A., Huber V., Gilch S., et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007, 21:936-942.
75. Crazzolara R., Bradstock K.F., Bendall L.J. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009, 5:727-728.
76. Crazzolara R., Cisterne A., Thien M., et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009, 113:3297-3306.
77. Itoh T., Ito Y., Ohguchi K., et al. Eupalinin A isolated from Eupatorium chinense L. induces autophagocytosis in human leukemia HL60 cells. Bioorg Med Chem 2008, 16:721-731.
78. Bredholt T., Dimba E.A., Hagland H.R., et al. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL. Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol Cancer 2009, 8:101.
79. Samudio I., Kurinna S., Ruvolo P., et al. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 2008, 7:1130-1139.
80. Ghavami S., Asoodeh A., Klonisch T., et al. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J Cell Mol Med 2008, 12:1005-1022.
81. Hurren R., Zavareh R.B., Dalili S., et al. A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death. Apoptosis 2008, 13:748-755.
82. Van Quaquebeke E., Mahieu T., Dumont P., et al. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-be nzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 2007, 50:4122-4134.
83. Wang J., Lian H., Zhao Y., Kauss M.A., Spindel S. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem 2008, 283:25596-25605.
84. Yokoyama T., Miyazawa K., Naito M., et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy 2008, 4:629-640.
85. Laane E., Tamm K.P., Buentke E., et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009, 16:1018-1029.
86. Grander D., Kharaziha P., Laane E., Pokrovskaja K., Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009, 5:1198-1200.
87. Chen Y.J., Huang W.P., Yang Y.C., et al. Platonin induces autophagy-associated cell death in human leukemia cells. Autophagy 2009, 5:173-183.
88. Kessel D., Arroyo A.S. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem Photobiol Sci 2007, 6:1290-1295.
89. Yang Y.P., Liang Z.Q., Gao B., Jia Y.L., Qin Z.H. Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol Sin 2008, 29:123-134.
90. Goussetis D.J., Altman J.K., Glaser H., McNeer J.L., Tallman M.S., Platanias L.C. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010, 285:29989-29997.
91. Charoensuk V., Gati W.P., Weinfeld M., Le X.C. Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol 2009, 239:64-70.
92. Schnekenburger M., Grandjenette C., Ghelfi J., et al. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol 2011, 81:364-378.
93. Zoppoli G., Cea M., Soncini D., et al. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010, 38:979-988.
94. Wei Y., Kadia T., Tong W., et al. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 2010, 6:976-978.
95. Gao P., Bauvy C., Souquere S., et al. The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 2010, 285:25570-25581.
96. Puissant A., Robert G., Fenouille N., et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010, 70:1042-1052.
97. Puissant A., Auberger P. AMPK- and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia. Autophagy 2010, 6.
98. Dunwell T., Hesson L., Rauch T.A., et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer 2010, 9:44.
99. Bonapace L., Bornhauser B.C., Schmitz M., et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010, 120:1310-1323.
100. Bellodi C., Lidonnici M.R., Hamilton A., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009, 119:1109-1123.
101. Mishima Y., Terui Y., Taniyama A., et al. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 2008, 99:2200-2208.
102. Salomoni P., Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy 2009, 5:1050-1051.
103. Kamitsuji Y., Kuroda J., Kimura S., et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ 2008, 15:1712-1722.
104. Ohtomo T., Miyazawa K., Naito M., et al. Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation. Biochem Biophys Res Commun 2010, 391:310-315.
105. Carew J.S., Nawrocki S.T., Kahue C.N., et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110:313-322.
106. Ren Y., Huang F., Liu Y., Yang Y., Jiang Q., Xu C. Autophagy inhibition through PI3 K/Akt increases apoptosis by sodium selenite in NB4 cells. BMB Rep 2009, 42:599-604.
107. Evangelisti C., Ricci F., Tazzari P., et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011, 226:822-831.
108. Wang Z., Cao L., Kang R., et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARalpha oncoprotein. Autophagy 2011, 7.
109. Crowley L.C., Elzinga B.M., O'Sullivan G.C., McKenna S.L. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol 2011, 86:38-47.
110. Liu L., Yang M., Kang R., et al. DAMP-mediated autophagy contributes to drug resistance. Autophagy 2011, 7:112-114.
111. Liu L., Yang M., Kang R., et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011, 25:23-31.
112. Amrein L., Soulieres D., Johnston J.B., Aloyz R. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res 2011, 35:99-102.
113. Yang C., Tong Y., Ni W., et al. Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther 2010, 17:109-119.
114. Kessel D., Reiners J.J. Apoptosis and autophagy after mitochondrial or endoplasmic reticulum photodamage. Photochem Photobiol 2007, 83:1024-1028.
115. Carew J.S., Nawrocki S.T., Cleveland J.L. Modulating autophagy for therapeutic benefit. Autophagy 2007, 3:464-467.
116. Carew J.S., Nawrocki S.T., Giles F.J., Cleveland J.L. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2008, 2:201-204.
117. Calabretta B., Salomoni P. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma 2011, 52(Suppl. 1):54-59.
118. Puissant A., Robert G., Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010, 9:3470-3478.
119. Ramser B., Kokot A., Metze D., Weiss N., Luger T.A., Bohm M. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol 2009, 129:2419-2426.
120. Chen N., Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol Ther 2011, 11:157-168.
121. Wilkinson S., O'Prey J., Fricker M., Ryan K.M. Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev 2009, 23:1283-1288.
122. Wilkinson S., Ryan K.M. Growth factor signaling permits hypoxia-induced autophagy by a HIF1alpha-dependent. BNIP3/3L-independent transcriptional program in human cancer cells. Autophagy 2009, 5:1068-1069.